The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. scPharmaceuticals Inc shares valued at $2,000,000 were purchased by ORBIMED ADVISORS LLC on Aug 13 ’24. At $4.00 per share, ORBIMED ADVISORS LLC acquired 500,000 shares. The insider’s holdings grew to 5,806,670 shares worth approximately $19.86 million following the completion of this transaction.
As published in their initiating research note from Craig Hallum on September 07, 2023, scPharmaceuticals Inc [SCPH] has been a Buy and the price target has been revised to $20. Analysts at Cowen started covering the stock with ‘”an Outperform”‘ outlook in a report released in early December. Earlier on October 11, 2022, SVB Leerink upgraded its rating. Their new recommendation was “an Outperform” for SCPH stock which previously was a “a Mkt perform”.
Analyzing SCPH Stock Performance
During the last five days, there has been a drop of approximately -3.39%. Over the course of the year, scPharmaceuticals Inc shares have dropped approximately -3.39%. Shares of the company reached a 52-week high of $3.75 on 01/06/25 and a 52-week low of $3.36 on 01/08/25. A 50-day SMA is recorded $3.64, while a 200-day SMA reached $4.35. Nevertheless, trading volume fell to 0.17 million shares from 0.53 million shares the previous day.
Support And Resistance Levels for scPharmaceuticals Inc (SCPH)
According to the 24-hour chart, there is a support level at 3.34, which, if violated, would cause prices to drop to 3.26. In the upper region, resistance lies at 3.52. The next price resistance is at 3.62. RSI (Relative Strength Index) is 45.66 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.08, which suggests the price will decrease in the coming days. Percent R is at 51.56%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
